SK Bioscience which is conducting phase 3 clinical trial of covid-19 vaccine would release the interim results of phase 1 and 2 clinical trials in this coming October.
Kim Hun CTO of SK Bioscience announced the plan explaining the company’s future plans of “GBP510,” a potential candidate material of covid-19, at “the 18th autumn conference of the Korean Vaccine Society 2021” which was held online.
Kim Hun said, “we have confirmed safety and efficacy in the phase 1 and 2 clinical trials conducted in the first half of this year based on which we have begun clinical trial phase 3. It showed five to six times higher neutralizing antibody then standard serum in patients in recovery which makes it on par with leading vaccines.”
Kim Hun added, “we would be able to disclose detailed clinical trial results after negotiations with CEPI(Coalition for Epidemic Preparedness Innovations) from October. CEPI is an international private organization created by governments and charities which came together to raise funds and it is providing support for the development of GBP510.
Kim said, “we would make every effort to make sure clinical trials don’t get delayed by working closely with International Vaccine Institute.” SK Bioscience is aiming to unveil it in South Korea and start supplying “Covax facility,” a global mechanism for equitable access to covid-19 vaccines, after putting an end to the clinical trials in the first half of next year.
Kim answered to the question about response plans to variants, “we are developing a master cell bank in order to respond to variants such as delta and beta. We would begin to conduct clinical trials of variants in order and make it like an influenza vaccine. SK Bioscience had developed a quadrivalent cell-based flu vaccine.
Cho Yang-Je director of technology department of EyeGene which entered clinical trials of the only covid-19 mRNA vaccine in South Korea also took part in the event and emphasized that his company’s vaccine is much safer than that of Moderna and Pfizer.
Cho said, “anaphylaxis occurred due to PEG(a kind of surfactant that is included in additives in vaccines of Moderna or Pfizer) is being reported worldwide compared to which EyeGene doesn’t use PEG fundamentally preventing anaphylaxis.”
Cho explained, “EyeGene vaccines trigger reaction (inflammation, etc.) only in the muscle that has taken the shot and other organs including the heart and the liver don’t get affected.”
Kang Chang-Yuil CEO of Cellid who is developing a one-shot adenovirus vector (carrier) covid-19 vaccine shared the status and plans of clinical trials in detail.
Cellid is conducting phase 2a clinical trial and it is also conducting phase 1 clinical trial of 40 people who changed the vector in order to increase productivity and reduce cost of production.
Kang said, “we are planning to complete administering phase 1 clinical trial subjects next week and all ongoing studies(clinical trials) will come to an end in the middle of next month which would be followed by phase 2b and 3 global clinical trials. We are trying to get approval from the WHO for those in October and those in Vietnam and Indonesia in mid-November.
Cellid is aiming at applying for an approval in the second quarter after completing all clinical trials in the first quarter next year.
Pangyo Technovalley is an innovation hub for global companies comparable to the Silicon Valley in the US, Zhongguancun in China, and STATION F in France. It is an Asia tech hub with 1,259 IT, BT, CT, and NT companies that possess innovative products and technologies. Located just south of the metropolitan area, it provides the best environment for Korean companies to do business with great transportation access and infrastructure.
Various high-tech companies are located in Pangyo Technovalley, and it is occupied by 64,000 full-time employees, many in their 20-30s. In terms of industry, the companies are engaged in information technology, contents technology, biotechnology, and nanotechnology.
With the support of innovative companies with global capabilities such as Kakao, Naver, AhnLab, Krafton, NCSoft, Nexon, and Hancom, companies in Pangyo Technovalley recorded 107 trillion won in sales last year. Investment and infrastructure growth in Pangyo is expected to continue, with the Metaverse hub entering Pangyo this year.